Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

385 results about "COPD" patented technology

A group of progressive lung disorders characterized by increasing breathlessness.

Methods, systems and devices for improving ventilation in a lung area

Methods, systems and devices are described for new modes of ventilation in which specific lung areas are ventilated with an indwelling trans-tracheobronchial catheter for the purpose of improving ventilation and reducing hyperinflation in that specific lung area, and for redistributing inspired air to other healthier lung areas, for treating respiratory disorders such as COPD, ARDS, SARS, CF, and TB. Trans-Tracheobronchial Segmental Ventilation (TTSV) is performed on either a naturally breathing or a mechanical ventilated patient by placing a uniquely configured indwelling catheter into a bronchus of a poorly ventilated specific lung area and providing direct ventilation to that area. The catheter can be left in place for extended periods without clinician attendance or vigilance. Ventilation includes delivery of respiratory gases, therapuetic gases or agents and evacuation of stagnant gases, mixed gases or waste fluids. Typically the catheter's distal tip is anchored without occluding the bronchus but optionally may intermittently or continuously occlude the bronchus. TTSV is optionally performed by insufflation only of the area, or by application of vacuum to the area, can include elevating or reducing the pressure in the targeted area to facilitate stagnant gas removal, or can include blocking the area to divert inspired gas to better functioning areas.
Owner:BREATHE TECHNOLOGIES INC

Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase

A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, bronchoconstriction, lung allergy(ies) or inflammation, and abnormal levels of adenosine, adenosine receptors, sensitivity to adenosine, lung surfactant and ubiquinone, such as pulmonary fibrosis, vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, COPD, RDS, ARDS, cancer, and others. The present treatment is effectively administered by itself for conditions without known therapies, as a substitute for therapies exhibiting undesirable side effects, or in combination with other treatments, e.g. before, during and after other respiratory system therapies, radiation, chemotherapy, antibody therapy and surgery, among others. Each of the agents of this invention may be administered directly into the respiratory system so that they gain direct access to the lungs, or by other effective routes of administration. A kit comprises a delivery device, the agents and instructions for its use.
Owner:EPIGENESIS PHARMA LLC

Methods, systems and devices for improving ventilation in a lung area

ActiveUS7588033B2Effective and direct cannulationIncrease hyperinflationTracheal tubesOperating means/releasing devices for valvesDiseasePrimary bronchus
Methods, systems and devices are described for new modes of ventilation in which specific lung areas are ventilated with an indwelling trans-tracheobronchial catheter for the purpose of improving ventilation and reducing hyperinflation in that specific lung area, and for redistributing inspired air to other healthier lung areas, for treating respiratory disorders such as COPD, ARDS, SARS, CF, and TB. Trans-Tracheobronchial Segmental Ventilation (TTSV) is performed on either a naturally breathing or a mechanical ventilated patient by placing a uniquely configured indwelling catheter into a bronchus of a poorly ventilated specific lung area and providing direct ventilation to that area. The catheter can be left in place for extended periods without clinician attendance or vigilance. Ventilation includes delivery of respiratory gases, therapeutic gases or agents and evacuation of stagnant gases, mixed gases or waste fluids. Typically the catheter's distal tip is anchored without occluding the bronchus but optionally may intermittently or continuously occlude the bronchus. TTSV is optionally performed by insufflation only of the area, or by application of vacuum to the area, can include elevating or reducing the pressure in the targeted area to facilitate stagnant gas removal, or can include blocking the area to divert inspired gas to better functioning areas.
Owner:BREATHE TECHNOLOGIES INC

Non-invasive and minimally invasive denervation methods and systems for performing the same

A system and method can be used to denervate at least a portion of a bronchial tree. An energy emitter of an instrument is percutaneously delivered to a treatment site and outputs energy to damage nerve tissue of the bronchial tree. The denervation procedure can be performed without damaging non-targeted tissue. Minimally invasive methods can be used to open airways to improve lung function in subjects with COPD, asthma, or the like. Different sections of the bronchial tree can be denervated while leaving airways intact to reduce recovery times.
Owner:NUVAIRA INC

Breathing assistance apparatus

A nasal cannula assembly is disclosed having a face mount part, in use resting against a user's face, which includes at least one nasal prong capable of being fitted into a person's nares. The cannula assembly also includes a manifold part, in fluid communication with the face mount part, having a single horizontal side gases entry. In particular, this cannula assembly is for supplying heated, humidified gases to a patient suffering from COPD. A tie or lanyard is disclosed for use with a breathing assistance apparatus such as a nasal cannula, face or nasal mask or tracheostomy connector. The tie or lanyard transfers the weight of the conduits supplying gases to the breathing assistance apparatus from the breathing assistance apparatus and distributes it onto the neck of the patient.
Owner:FISHER & PAYKEL HEALTHCARE LTD

Direct lung sensor systems, methods, and apparatuses

InactiveUS20110201956A1Direct and accurate and simple and minimally invasiveAccurate healthRespiratorsBronchoscopesCOPDOptimal treatment
Devices, systems, and methods for diagnosing physiological parameters of the lungs and treating associated medical conditions are disclosed herein. In particular, certain embodiments permit detection of air flow in lung passageways, air leaks, gas concentration (in particular oxygen), and temperature measurements. Measurements obtained using the devices, systems, and methods disclosed herein may also be used to determine optimal treatment sites for medical conditions such as emphysema, COPD, or lung volume reduction.
Owner:GYRUS ACMI INC (D B A OLYMPUS SURGICAL TECH AMERICA)

Methods and compositions for disease treatment using inhalation

InactiveUS20120077786A1Increasing subject 's convenienceGood treatment complianceBiocideOrganic active ingredientsPulmonary edemaLung cancer
Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.
Owner:MICRODOSE THERAPEUTX INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products